Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 35  |  Issue : 3  |  Page : 1459-1464

Role of fenofibrate in reduction of central macular thickness in diabetic macular edema


1 Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Internal Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Correspondence Address:
Amany M S. El-Banna
Faculty of Medicine, Menoufia University, Yassin Abdelghaffar Street, Shebin El-Kom, Menoufia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_281_21

Rights and Permissions

Objective To study the benefit of addition of oral fenofibrate to the standard management of diabetic macular edema (DME) regarding central macular thickness (CMT) and visual function. Background DME is the commonest cause of vision loss in diabetes. Systemic therapy for DME largely meant control of diabetes, hypertension, and lipid levels. A revival in the use of systemic medication for a local condition caused by a systemic disease has occurred recently with hypolipidemic drugs, namely, atorvastatin and fenofibrate. Patients and methods Our study was a randomized controlled trial. It included 100 eyes of patients with type-2 diabetes complicated with DME. Patients were randomized into two groups: treatment group (oral fenofibrate) and control group (receiving placebo). Both groups underwent treatment of DME as per the standard treatment protocol of our hospital, including intravitreal injections and grid laser. Patients were followed up after 3 and 6 months to note the CMT and visual acuity. Results There was a significant lower mean value of CMT with higher mean value of percent reduction (19.22 vs. 13.256%) and higher mean value of visual acuity in fenofibrate group than the control group after 6 months of treatment. Conclusions Adding of fenofibrate (dose of 160 mg/day for 6 months) to standard protocols of DME treatment has beneficial effect on percent reduction in CMT and visual acuity.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed406    
    Printed32    
    Emailed0    
    PDF Downloaded49    
    Comments [Add]    

Recommend this journal